India's bioeconomy to reach US $300 billion by 2030: Dr. Jitendra Singh
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
e brings over 27+ years of rich pharmaceutical experience
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
MoCRA mandates that all facilities involved in the manufacturing and processing of cosmetic products for sale in the United States
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Subscribe To Our Newsletter & Stay Updated